Technosphere Insulin: Defining the Role of Technosphere Particles at the Cellular Level

Overview

Journal J Diabetes Sci Technol

Specialty Endocrinology

Date 2010 Feb 11

PMID 20144294

Citations 24

Authors

Robert Angelo

Kathleen Rousseau

Marshall Grant

Andrea Leone-Bay

Peter Richardson

Affiliations

Soon will be listed here.

Abstract

Background: Technosphere Insulin (TI) is a novel inhalation powder for the treatment of diabetes mellitus. Technosphere Insulin delivers insulin with an ultra rapid pharmacokinetic profile that is distinctly different from all other insulin products but similar to natural insulin release. Such rapid absorption is often associated with penetration enhancers that disrupt cellular integrity.

Methods: Technosphere Insulin was compared to a panel of known penetration enhancers in vitro using the Calu-3 lung cell line to investigate the effects of TI on insulin transport.

Results: Measures of tight junction integrity such as transepithelial electrical resistance, Lucifer yellow permeability, and F-actin staining patterns were all unaffected by TI. Cell viability and plasma membrane integrity were also not affected by TI. In contrast, cells treated with comparable (or lower) concentrations of penetration enhancers showed elevated Lucifer yellow permeability, disruption of the F-actin network, reduced cell viability, and compromised plasma membranes.

Conclusions: These results demonstrate that TI is not cytotoxic in an in vitro human lung cell model and does not function as a penetration enhancer. Furthermore, TI does not appear to affect the transport of insulin across cellular barriers.

Citing Articles

Different Carriers for Use in Dry Powder Inhalers: Characteristics of Their Particles.

Salustio P, Amaral M, Costa P J Aerosol Med Pulm Drug Deliv. 2024; 37(6):307-327.

PMID: 39120712 PMC: 11669763. DOI: 10.1089/jamp.2023.0029.

Pulmonary inhalation for disease treatment: Basic research and clinical translations.

Wang B, Wang L, Yang Q, Zhang Y, Qinglai T, Yang X Mater Today Bio. 2024; 25:100966.

PMID: 38318475 PMC: 10840005. DOI: 10.1016/j.mtbio.2024.100966.

Insulin Therapy for the Management of Diabetes Mellitus: A Narrative Review of Innovative Treatment Strategies.

Nkonge K, Nkonge D, Nkonge T Diabetes Ther. 2023; 14(11):1801-1831.

PMID: 37736787 PMC: 10570256. DOI: 10.1007/s13300-023-01468-4.

Advanced Formulation Approaches for Proteins.

Schlosser C, Williams G, Dziemidowicz K Handb Exp Pharmacol. 2023; 284:69-91.

PMID: 37059912 DOI: 10.1007/164_2023_647.

Advancements in the Design and Development of Dry Powder Inhalers and Potential Implications for Generic Development.

Mohan A, Wang Q, Dhapare S, Bielski E, Kaviratna A, Han L Pharmaceutics. 2022; 14(11).

PMID: 36432683 PMC: 9695470. DOI: 10.3390/pharmaceutics14112495.

References

Sayani A, Chien Y . Systemic delivery of peptides and proteins across absorptive mucosae. Crit Rev Ther Drug Carrier Syst. 1996; 13(1-2):85-184. View

Chesnut 3rd C, Azria M, Silverman S, Engelhardt M, Olson M, Mindeholm L . Salmon calcitonin: a review of current and future therapeutic indications. Osteoporos Int. 2007; 19(4):479-91. DOI: 10.1007/s00198-007-0490-1. View

Cano-Cebrian M, Zornoza T, Granero L, Polache A . Intestinal absorption enhancement via the paracellular route by fatty acids, chitosans and others: a target for drug delivery. Curr Drug Deliv. 2005; 2(1):9-22. DOI: 10.2174/1567201052772834. View

Bahhady R, Kim K, Borok Z, Crandall E, Shen W . Enhancement of insulin transport across primary rat alveolar epithelial cell monolayers by endogenous cellular factor(s). Pharm Res. 2007; 24(9):1713-9. DOI: 10.1007/s11095-007-9301-9. View

Mathia N, Timoszyk J, Stetsko P, Megill J, Smith R, Wall D . Permeability characteristics of calu-3 human bronchial epithelial cells: in vitro-in vivo correlation to predict lung absorption in rats. J Drug Target. 2002; 10(1):31-40. DOI: 10.1080/10611860290007504. View

Wang Z, Zhang Q . Transport of proteins and peptides across human cultured alveolar A549 cell monolayer. Int J Pharm. 2004; 269(2):451-6. DOI: 10.1016/j.ijpharm.2003.09.033. View

Daugherty A, Mrsny R . Emerging technologies that overcome biological barriers for therapeutic protein delivery. Expert Opin Biol Ther. 2003; 3(7):1071-81. DOI: 10.1517/14712598.3.7.1071. View

Brain J . Inhalation, deposition, and fate of insulin and other therapeutic proteins. Diabetes Technol Ther. 2007; 9 Suppl 1:S4-S15. DOI: 10.1089/dia.2007.0228. View

Florea B, Cassara M, Junginger H, Borchard G . Drug transport and metabolism characteristics of the human airway epithelial cell line Calu-3. J Control Release. 2003; 87(1-3):131-8. DOI: 10.1016/s0168-3659(02)00356-5. View

10.

Geys J, Coenegrachts L, Vercammen J, Engelborghs Y, Nemmar A, Nemery B . In vitro study of the pulmonary translocation of nanoparticles: a preliminary study. Toxicol Lett. 2005; 160(3):218-26. DOI: 10.1016/j.toxlet.2005.07.005. View

11.

Hussain A, Arnold J, Khan M, Ahsan F . Absorption enhancers in pulmonary protein delivery. J Control Release. 2003; 94(1):15-24. DOI: 10.1016/j.jconrel.2003.10.001. View

12.

Yu J, Chien Y . Pulmonary drug delivery: physiologic and mechanistic aspects. Crit Rev Ther Drug Carrier Syst. 1997; 14(4):395-453. View

13.

Coyne C, Ribeiro C, Boucher R, Johnson L . Acute mechanism of medium chain fatty acid-induced enhancement of airway epithelial permeability. J Pharmacol Exp Ther. 2003; 305(2):440-50. DOI: 10.1124/jpet.102.047654. View

14.

Patton J, Fishburn C, Weers J . The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc. 2005; 1(4):338-44. DOI: 10.1513/pats.200409-049TA. View

15.

Brown L . Commercial challenges of protein drug delivery. Expert Opin Drug Deliv. 2005; 2(1):29-42. DOI: 10.1517/17425247.2.1.29. View

16.

Steimer A, Haltner E, Lehr C . Cell culture models of the respiratory tract relevant to pulmonary drug delivery. J Aerosol Med. 2005; 18(2):137-82. DOI: 10.1089/jam.2005.18.137. View

17.

Pfutzner A, Mann A, Steiner S . Technosphere/Insulin--a new approach for effective delivery of human insulin via the pulmonary route. Diabetes Technol Ther. 2002; 4(5):589-94. DOI: 10.1089/152091502320798204. View

18.

Krysiak R, Gdula-Dymek A, Bednarska-Czerwinska A, Okopien B . Growth hormone therapy in children and adults. Pharmacol Rep. 2007; 59(5):500-16. View

19.

Grainger C, Greenwell L, Lockley D, Martin G, Forbes B . Culture of Calu-3 cells at the air interface provides a representative model of the airway epithelial barrier. Pharm Res. 2006; 23(7):1482-90. DOI: 10.1007/s11095-006-0255-0. View

20.

Salamat-Miller N, Johnston T . Current strategies used to enhance the paracellular transport of therapeutic polypeptides across the intestinal epithelium. Int J Pharm. 2005; 294(1-2):201-16. DOI: 10.1016/j.ijpharm.2005.01.022. View